WHO ICTRP trial
Treatment for acute myeloid leukemia (AML) during its first complete remision…
EUCTR2005-000640-91-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2005-000640-91-ES |
|---|---|
| Public title | Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cells |
| Scientific title | Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cells |
| Primary sponsor | Institut de Recerca Hospital Sta. Creu i St. Pau |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Spain |
| Conditions | Acute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplant |
| Interventions | Trade Name: Mylotarg Product Name: Mylotarg Pharmaceutical Form: Injection* INN or Proposed INN: GENTUZUMAB OZOGAMICINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- |
| Registration date | May 17, 2006 |
| Target size | 20 |
| Secondary IDs | CMA-RC-03 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: